Biosimilar Cost-Savings Needed To Balance Extrapolation Risk, Advisors Tell FDA
Executive Summary
Inflectra should be priced considerably lower than Remicade given that approval for some indications would be based on extrapolation, advisory committee members said; Celltrion exec suggests price could approximate the 30% discount seen in Europe.